12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Company News  |  Deals

Genmab, Immunex, Medarex deal

Genmab received exclusive worldwide rights to develop antibodies against IL-15, a cytokine implicated in a variety of inflammatory conditions. The rights were obtained from IMNX through a sublicense from MEDX, which formed...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >